Home > Insider Trading > Filing (0001140361-18-029017)

Filing Details

Accession Number:: 0001140361-18-029017
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-18 17:36:58
Reporting Period:: 2018-06-15

Accepted Time:: 2018-06-18 17:36:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1561387	Health Insurance Innovations Inc.	HIIQ	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1411509	John Fichthorn	119 Rowayton Avenue Norwalk CT 06853		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-06-15	18,414	$34.98	192,586	No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
Common Stock	Disposition	2018-06-18	67,163	$34.40	125,423	No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
Common Stock	Disposition	2018-06-19	27,223	$33.95	98,200	No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
Common Stock	Acquisiton	2018-06-19	11,162	$33.95	109,362	No	4	P	Indirect	Held by Dialectic Antithesis Partners, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
No	4	S	Indirect	Held by Dialectic Antithesis Partners, LP
No	4	P	Indirect	Held by Dialectic Antithesis Partners, LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,608	Direct
Common Stock	82,258	Indirect	Held by BRC Partners Opportunity Fund, LP

Footnotes

Represents transactions to rebalance the assets in a fund for which the Reporting Person is a portfolio manager. Reporting Person disclaims beneficial ownership of the Issuer's securities held by the fund except to the extent of a small pecuniary interest held by the Reporting Person in the fund.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.725 to $35.1551, inclusive. The Reporting Person undertakes to provide Health Insurance Innovations, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
BR Dialectic Capital Management, LLC is the investment manager of Dialectic Antithesis Partners, LP and, as such, shares voting and dispositive power over the securities held by Dialectic Antithesis Partners, LP. B. Riley Capital Management, LLC is the investment manager of BRC Partners Opportunity Fund, LP (the "BRC Opportunity Fund") and, as such, shares voting and dispositive power over the securities held by the BRC Opportunity Fund. The Reporting Person is a portfolio manager for BR Dialectic Capital Management, LLC and B. Riley Capital Management, LLC and therefore shares voting and dispositive power over the securities, but the Reporting Person disclaims beneficial ownership of any of Issuer's securities in which he does not have a pecuniary interest or that he does not directly own. BR Dialectic Capital Management, LLC and B. Riley Capital Management, LLC are wholly owned subsidiaries of B. Riley Financial, Inc., a publicly traded Delaware corporation (NasdaqCM: RILY).
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.1227 to $34.6669, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.778 to $34.2241, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $33.8233 to $34.2261, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.